查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858923

2025-2035年全球基因組生物標記市場

Global Genomic Biomarker Market 2025-2035
出版日期: | 出版商: Orion Market Research | 英文 175 Pages | 商品交期: 2-3個工作天內

價格

基因組生物標記市場規模、佔有率及趨勢分析報告，按類型（預測性生物標記和預後性生物標記）、疾病適應症（腫瘤、心血管疾病、神經系統疾病、腎臟疾病及其他）和最終用戶（診斷和研究實驗室、醫院及其他）分類，預測期（2025-2035 年）。

行業概覽

目錄

第1章：報告摘要

  • 目前行業分析及成長潛力展望
  • 全球基因組生物標記市場銷售分析 - 類型 | 疾病適應症 | 最終用戶（百萬美元）
  • 主要國家的基因組生物標記市場銷售業績
  • 研究方法
  • 主要研究方法
  • 二手研究方法
  • 市場概況

第2章：市場概覽與洞察

  • 研究範圍
  • 分析師洞察與當前市場趨勢
    • 基因組生物標記產業關鍵趨勢
    • 市場建議

第3章：市場決定因素

  • 市場促進因素
    • 全球基因組生物標記市場促進因素：影響分析
  • 市場痛點與挑戰
    • 全球基因組生物標記市場限制因素：影響分析
  • 市場機遇
    • 全球基因組生物標記市場機會：影響分析

第4章：競爭格局

  • Competitive Dashboard - Genomic Biomarker Market Revenue and Share by Manufacturers
  • Genomic Biomarker Product Comparison Analysis
  • Top Market Player Ranking Matrix
  • 重點公司分析
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Illumina
    • QIAGEN
    • Thermo Fisher Scientific
  • Top Winning Strategies by Market Players
    • Merger and Acquisition
    • Product Launch
    • Partnership And Collaboration

第5章：全球基因組生物標記市場銷售分析（按類型分類，單位：百萬美元）

  • 預測性生物標記
  • 預後生物標記

第6章：全球基因組生物標記市場銷售分析（依疾病適應症分類，單位：百萬美元）

  • 腫瘤學
  • 心血管疾病
  • 神經系統疾病
  • 腎臟疾病
  • 其他

第7章：全球基因組生物標記市場最終用戶銷售分析（百萬美元）

  • 診斷與研究實驗室
  • 醫院
  • 其他

第8章：區域分析

  • 北美基因組生物標記市場銷售分析 - 類型 | 疾病適應症 | 技術 | 最終用戶（百萬美元）
  • 北美宏觀經濟因素
    • 美國
    • 加拿大
  • 歐洲基因組生物標記市場銷售分析 - 類型 | 疾病適應症 | 技術 | 最終用戶（百萬美元）
  • 歐洲宏觀經濟因素
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 俄羅斯
    • 歐洲其他地區
  • 亞太地區基因組生物標記市場銷售分析 - 類型 | 疾病適應症 | 最終用戶（百萬美元）
  • 亞太地區的宏觀經濟因素
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲和紐西蘭
    • 東協國家（泰國、印尼、越南、新加坡等）
    • 亞太其他地區
  • 全球其他地區基因組生物標記市場銷售分析 - 類型 | 疾病適應症 | 機構規模 | 疾病適應症 | 技術 | 最終用戶（百萬美元）
  • 世界其他地區的宏觀經濟因素
    • 拉丁美洲
    • 中東和非洲

第9章：公司簡介

  • Agilent Technologies
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Almac Group
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • BGI Genomics
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Bio-Rad Laboratories
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Cancer Genetics, Inc. (CGI)
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Caris Life Sciences
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Danaher Corp.
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Epigenomics AG
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Eurofins Scientific
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Exact Sciences
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • F. Hoffmann-La Roche
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Guardant Health
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Illumina
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • LabCorp
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Myriad Genetics
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • PerkinElmer
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Qiagen
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Tempus
    • Quick Facts
    • Company Overview
    • Product Portfolio
    • Business Strategies
  • Thermo Fisher Scientific
  • Quick Facts
  • Company Overview
  • Product Portfolio
  • Business Strategies
Product Code: OMR2023964

Genomic Biomarker Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, and Prognostic Biomarkers) by Disease Indication (Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, and Others), and by End-User (Diagnostic and Research Laboratories, Hospitals, and Others) Forecast Period (2025-2035)

Industry Overview

Genomic biomarker market was valued at $8.4 billion in 2024 and is projected to reach $41.7 billion by 2035, growing at a CAGR of 15.8% during the forecast period (2025-2035). Genomic biomarkers are DNA and RNA traits used as diagnostic indicators, disease characterization, and therapy selection tools. The body's response to treatment, as well as pathological and physiological processes, is represented by genomic biomarkers. Testing for genomic biomarkers can find molecular changes in a single gene, a group of genes, or a whole genome. A relationship between a genetic biomarker and the likelihood of developing a disease may or may not have strong supporting data. Functional laboratory evaluations and genetic epidemiology evidence are two variables that contribute to the clinical validity and usability of genomic biomarkers. The growing innovation in the healthcare industry by using novel medicines, increasing research & development programs to diagnose chronic diseases, and growing proliferation of minimally invasive procedures are positively influencing the genomic biomarkers market. In addition, the rising focus on the availability of personalized medicines for enabling better patient care, along with favorable government initiatives relating to genomic research, is additionally augmenting the growth of the global market.

Market Dynamics

Clinical Demand from Precision Oncology and Targeted Therapies

The largest immediate growth engine is oncology: as more targeted drugs and immunotherapies require genomic stratification, both predictive and prognostic biomarkers are embedded into standard-of-care pathways and clinical trials. Companion diagnostic requirements and payer-backed indications for molecular tests push hospitals and reference labs to adopt standardized genomic panels and reporting workflows, increasing test volumes and market revenues.

Technology Advances That Lower Cost and Expand Utility (NGS, CTDNA, Single-Cell, Bioinformatics)

Ongoing declines in sequencing costs, improvements in throughput (NGS platforms), and maturation of liquid-biopsy assays (ctDNA) reduce per-patient testing cost and make broader screening, monitoring, and minimal residual disease (MRD) applications commercially feasible. Better bioinformatics, variant interpretation platforms, and cloud-based reporting tools also raise the clinical utility of genomic biomarkers, accelerating uptake across hospitals and labs.

Regulatory, Reimbursement, and Pharma Partnerships Enabling Commercialization

Regulatory clarity for companion diagnostics, growing reimbursement coverage for high-value genomic tests, and strategic co-development deals between diagnostics firms and pharma (to support targeted therapy launches) materially improve commercial viability. These structural enables reduce payer uncertainty and create predictable revenue paths for both assay providers and profiling labs - while M&A accelerates capability scale.

Market Segmentation

  • Based on the type, the market is segmented into predictive biomarkers and prognostic biomarkers.
  • Based on the disease indication, the market is segmented into oncology, cardiovascular diseases, neurological diseases, renal disorders, and others.
  • Based on the end-user, the market is segmented into diagnostic and research laboratories, hospitals, and others.

Oncology Largest Segment in the Global Genomic Biomarker Market

Oncology under the disease indication segment leads with the largest share. Cancer remains the single biggest therapeutic area where genomic biomarkers are integrated into clinical care, research, and drug development pipelines. Precision oncology relies extensively on genomic insights, with predictive and prognostic biomarkers guiding not only diagnosis but also therapeutic selection, risk assessment, and disease monitoring. The need to match patients with targeted therapies or immunotherapies has made oncology biomarker testing indispensable in both developed and emerging healthcare systems.

Predictive Biomarkers: A Key Segment in Market Growth

The predictive biomarkers segment by type is emerging as the fastest-growing area within the global genomic biomarker market. Predictive biomarkers are critical because they directly inform treatment response and therapeutic decision-making, making them indispensable for precision medicine. The rapid expansion of companion diagnostics, especially in oncology, neurology, and cardiovascular diseases, has created a strong pipeline for predictive biomarker adoption.

Pharmaceutical companies are increasingly integrating predictive biomarkers early in clinical development to improve the success rates of drug candidates and to design adaptive trials. Additionally, the growing acceptance of genomic testing by healthcare providers and patients, coupled with reimbursement improvements, is accelerating the adoption of predictive biomarkers globally. As new targeted drugs enter the market, predictive biomarker demand will likely outpace prognostic and other biomarker categories, making it the key driver of growth over the coming decade.

Regional Outlook

The global genomic biomarker industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

North America holds a significant share of the global genomic biomarker market. The US dominates the global genomic biomarker market with the largest share, driven by its advanced healthcare infrastructure, strong presence of leading biotechnology and pharmaceutical companies, and high investment in precision medicine. The US benefits from being home to major industry leaders such as Illumina, Thermo Fisher Scientific, Roche's Foundation Medicine, Guardant Health, Myriad Genetics, and Tempus, which spearhead biomarker research, clinical diagnostics, and commercialization of genomic tests. Extensive adoption of genomic biomarkers in oncology, particularly in companion diagnostics for targeted therapies and immunotherapies, has cemented the country's leadership position.

Market Players Outlook

The major companies operating in the global genomic biomarker market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Illumina, QIAGEN, Thermo Fisher Scientific, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

  • In March 2025, LuNGS Alliance launched free lung NGS biomarker testing for lung cancer patients in India, backed by AstraZeneca, Pfizer, and Roche. The initiative, backed by 4baseCare, aims to promote precision oncology as an accessible and affordable treatment plan. The test analyzes 72 mutated genes, identifying actionable biomarkers for personalized treatment plans.
  • In August 2024, the FDA approved the TruSight Oncology TruSight Comprehensive test, which uses over 500 genes to profile solid tumors. This test can identify immuno-oncology biomarkers or clinically actionable biomarkers, enabling targeted therapy options or clinical trial enrollment. It is also approved for adult patients with solid tumors positive for NTRK gene fusions and NSCLC fusion-positive NSCLC.

The Report Covers:

  • Market value data analysis of 2024 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global genomic biomarker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Global Genomic Biomarker Market Sales Analysis - Type | Disease Indication | End-User ($ Million)
  • Genomic Biomarker Market Sales Performance of Top Countries
  • 1.1. Research Methodology
  • Primary Research Approach
  • Secondary Research Approach
  • 1.2. Market Snapshot

2. Market Overview and Insights

  • 2.1. Scope of the Study
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Genomic Biomarker Industry Trends
    • 2.2.2. Market Recommendations

3. Market Determinants

  • 3.1. Market Drivers
    • 3.1.1. Drivers For Global Genomic Biomarker Market: Impact Analysis
  • 3.2. Market Pain Points and Challenges
    • 3.2.1. Restraints For Global Genomic Biomarker Market: Impact Analysis
  • 3.3. Market Opportunities
    • 3.3.1. Opportunities For Global Genomic Biomarker Market: Impact Analysis

4. Competitive Landscape

  • 4.1. Competitive Dashboard - Genomic Biomarker Market Revenue and Share by Manufacturers
  • Genomic Biomarker Product Comparison Analysis
  • Top Market Player Ranking Matrix
  • 4.2. Key Company Analysis
    • 4.2.1. Bio-Rad Laboratories, Inc.
      • 4.2.1.1. Overview
      • 4.2.1.2. Product Portfolio
      • 4.2.1.3. Financial Analysis (Subject to Data Availability)
      • 4.2.1.4. SWOT Analysis
      • 4.2.1.5. Business Strategy
    • 4.2.2. F. Hoffmann-La Roche Ltd.
      • 4.2.2.1. Overview
      • 4.2.2.2. Product Portfolio
      • 4.2.2.3. Financial Analysis (Subject to Data Availability)
      • 4.2.2.4. SWOT Analysis
      • 4.2.2.5. Business Strategy
    • 4.2.3. Illumina
      • 4.2.3.1. Overview
      • 4.2.3.2. Product Portfolio
      • 4.2.3.3. Financial Analysis (Subject to Data Availability)
      • 4.2.3.4. SWOT Analysis
      • 4.2.3.5. Business Strategy
    • 4.2.4. QIAGEN
      • 4.2.4.1. Overview
      • 4.2.4.2. Product Portfolio
      • 4.2.4.3. Financial Analysis (Subject to Data Availability)
      • 4.2.4.4. SWOT Analysis
      • 4.2.4.5. Business Strategy
    • 4.2.5. Thermo Fisher Scientific
      • 4.2.5.1. Overview
      • 4.2.5.2. Product Portfolio
      • 4.2.5.3. Financial Analysis (Subject to Data Availability)
      • 4.2.5.4. SWOT Analysis
      • 4.2.5.5. Business Strategy
  • 4.3. Top Winning Strategies by Market Players
    • 4.3.1. Merger and Acquisition
    • 4.3.2. Product Launch
    • 4.3.3. Partnership And Collaboration

5. Global Genomic Biomarker Market Sales Analysis By Type ($ Million)

  • 5.1. Predictive Biomarkers
  • 5.2. Prognostic Biomarkers

6. Global Genomic Biomarker Market Sales Analysis By Disease Indication ($ Million)

  • 6.1. Oncology
  • 6.2. Cardiovascular Diseases
  • 6.3. Neurological Diseases
  • 6.4. Renal Disorders
  • 6.5. Others

7. Global Genomic Biomarker Market Sales Analysis By End-User ($ Million)

  • 7.1. Diagnostic and Research Laboratories
  • 7.2. Hospitals
  • 7.3. Others

8. Regional Analysis

  • 8.1. North American Genomic Biomarker Market Sales Analysis - Type | Disease Indication| Disease Indication| Technology | End-User ($ Million)
  • Macroeconomic Factors for North America
    • 8.1.1. United States
    • 8.1.2. Canada
  • 8.2. European Genomic Biomarker Market Sales Analysis - Type | Disease Indication| Disease Indication| Technology | End-User ($ Million)
  • Macroeconomic Factors for Europe
    • 8.2.1. UK
    • 8.2.2. Germany
    • 8.2.3. Italy
    • 8.2.4. Spain
    • 8.2.5. France
    • 8.2.6. Russia
    • 8.2.7. Rest of Europe
  • 8.3. Asia-Pacific Genomic Biomarker Market Sales Analysis - Type | Disease Indication | End-User ($ Million)
  • Macroeconomic Factors for Asia-Pacific
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
    • 8.3.4. India
    • 8.3.5. Australia & New Zealand
    • 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
    • 8.3.7. Rest of Asia-Pacific
  • 8.4. Rest of the World Genomic Biomarker Market Sales Analysis - Type | Disease Indication| Organization Size | Disease Indication | Technology | End-User ($ Million)
  • Macroeconomic Factors for the Rest of the World
    • 8.4.1. Latin America
    • 8.4.2. Middle East and Africa

9. Company Profiles

  • 9.1. Agilent Technologies
    • 9.1.1. Quick Facts
    • 9.1.2. Company Overview
    • 9.1.3. Product Portfolio
    • 9.1.4. Business Strategies
  • 9.2. Almac Group
    • 9.2.1. Quick Facts
    • 9.2.2. Company Overview
    • 9.2.3. Product Portfolio
    • 9.2.4. Business Strategies
  • 9.3. BGI Genomics
    • 9.3.1. Quick Facts
    • 9.3.2. Company Overview
    • 9.3.3. Product Portfolio
    • 9.3.4. Business Strategies
  • 9.4. Bio-Rad Laboratories
    • 9.4.1. Quick Facts
    • 9.4.2. Company Overview
    • 9.4.3. Product Portfolio
    • 9.4.4. Business Strategies
  • 9.5. Cancer Genetics, Inc. (CGI)
    • 9.5.1. Quick Facts
    • 9.5.2. Company Overview
    • 9.5.3. Product Portfolio
    • 9.5.4. Business Strategies
  • 9.6. Caris Life Sciences
    • 9.6.1. Quick Facts
    • 9.6.2. Company Overview
    • 9.6.3. Product Portfolio
    • 9.6.4. Business Strategies
  • 9.7. Danaher Corp.
    • 9.7.1. Quick Facts
    • 9.7.2. Company Overview
    • 9.7.3. Product Portfolio
    • 9.7.4. Business Strategies
  • 9.8. Epigenomics AG
    • 9.8.1. Quick Facts
    • 9.8.2. Company Overview
    • 9.8.3. Product Portfolio
    • 9.8.4. Business Strategies
  • 9.9. Eurofins Scientific
    • 9.9.1. Quick Facts
    • 9.9.2. Company Overview
    • 9.9.3. Product Portfolio
    • 9.9.4. Business Strategies
  • 9.10. Exact Sciences
    • 9.10.1. Quick Facts
    • 9.10.2. Company Overview
    • 9.10.3. Product Portfolio
    • 9.10.4. Business Strategies
  • 9.11. F. Hoffmann-La Roche
    • 9.11.1. Quick Facts
    • 9.11.2. Company Overview
    • 9.11.3. Product Portfolio
    • 9.11.4. Business Strategies
  • 9.12. Guardant Health
    • 9.12.1. Quick Facts
    • 9.12.2. Company Overview
    • 9.12.3. Product Portfolio
    • 9.12.4. Business Strategies
  • 9.13. Illumina
    • 9.13.1. Quick Facts
    • 9.13.2. Company Overview
    • 9.13.3. Product Portfolio
    • 9.13.4. Business Strategies
  • 9.14. LabCorp
    • 9.14.1. Quick Facts
    • 9.14.2. Company Overview
    • 9.14.3. Product Portfolio
    • 9.14.4. Business Strategies
  • 9.15. Myriad Genetics
    • 9.15.1. Quick Facts
    • 9.15.2. Company Overview
    • 9.15.3. Product Portfolio
    • 9.15.4. Business Strategies
  • 9.16. PerkinElmer
    • 9.16.1. Quick Facts
    • 9.16.2. Company Overview
    • 9.16.3. Product Portfolio
    • 9.16.4. Business Strategies
  • 9.17. Qiagen
    • 9.17.1. Quick Facts
    • 9.17.2. Company Overview
    • 9.17.3. Product Portfolio
    • 9.17.4. Business Strategies
  • 9.18. Tempus
    • 9.18.1. Quick Facts
    • 9.18.2. Company Overview
    • 9.18.3. Product Portfolio
    • 9.18.4. Business Strategies
  • 9.19. Thermo Fisher Scientific
  • 9.20. Quick Facts
  • 9.21. Company Overview
  • 9.22. Product Portfolio
  • 9.23. Business Strategies

LIST OF TABLES

  • 1. Global Genomic Biomarker Market Research and Analysis By Type, 2024-2035 ($ Million)
  • 2. Global Predictive Genomic Biomarker Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 3. Global Prognostic Genomic Biomarker Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 4. Global Genomic Biomarker Market Research and Analysis By Disease Indication, 2024-2035 ($ Million)
  • 5. Global Genomic Biomarker For Oncology Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 6. Global Genomic Biomarker For Cardiovascular Diseases Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 7. Global Genomic Biomarker For Neurological Diseases Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 8. Global Genomic Biomarker For Renal Disorders Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 9. Global Genomic Biomarker For Other End User Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 10. Global Genomic Biomarker Market Research and Analysis By End-User Industry, 2024-2035 ($ Million)
  • 11. Global Genomic Biomarker For Diagnostic and Research Laboratories Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 12. Global Genomic Biomarker For Hospitals Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 13. Global Genomic Biomarker For Other End User Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 14. Global Genomic Biomarker Market Research and Analysis By Region, 2024-2035 ($ Million)
  • 15. North American Genomic Biomarker Market Research and Analysis By Country, 2024-2035 ($ Million)
  • 16. North American Genomic Biomarker Market Research and Analysis By Type, 2024-2035 ($ Million)
  • 17. North American Genomic Biomarker Market Research and Analysis By Disease Indication, 2024-2035 ($ Million)
  • 18. North American Genomic Biomarker Market Research and Analysis By End-User, 2024-2035 ($ Million)
  • 19. European Genomic Biomarker Market Research and Analysis By Country, 2024-2035 ($ Million)
  • 20. European Genomic Biomarker Market Research and Analysis By Type, 2024-2035 ($ Million)
  • 21. European Genomic Biomarker Market Research and Analysis By Disease Indication, 2024-2035 ($ Million)
  • 22. European Genomic Biomarker Market Research and Analysis By End-User, 2024-2035 ($ Million)
  • 23. Asia-Pacific Genomic Biomarker Market Research and Analysis By Country, 2024-2035 ($ Million)
  • 24. Asia-Pacific Genomic Biomarker Market Research and Analysis By Type, 2024-2035 ($ Million)
  • 25. Asia-Pacific Genomic Biomarker Market Research and Analysis By Disease Indication, 2024-2035 ($ Million)
  • 26. Asia-Pacific Genomic Biomarker Market Research and Analysis By End-User, 2024-2035 ($ Million)
  • 27. Rest Of The World Genomic Biomarker Market Research and Analysis By Country, 2024-2035 ($ Million)
  • 28. Rest Of The World Genomic Biomarker Market Research and Analysis By Type, 2024-2035 ($ Million)
  • 29. Rest Of The World Genomic Biomarker Market Research and Analysis By Disease Indication, 2024-2035 ($ Million)
  • 30. Rest Of The World Genomic Biomarker Market Research and Analysis By End-User, 2024-2035 ($ Million)

LIST OF FIGURES

  • 1. Global Genomic Biomarker Market Share By Type, 2024 Vs 2035 (%)
  • 2. Global Predictive Genomic Biomarker Market Share By Region, 2024 Vs 2035 (%)
  • 3. Global Prognostic Biomarker Services Market Share By Region, 2024 Vs 2035 (%)
  • 4. Global Genomic Biomarker Market Share By Disease Indication, 2024 Vs 2035 (%)
  • 5. Global Genomic Biomarker For Oncology Market Share By Region, 2024 Vs 2035 (%)
  • 6. Global Genomic Biomarker For Cardiovascular Diseases Market Share By Region, 2024 Vs 2035 (%)
  • 7. Global Genomic Biomarker For Neurological Diseases Market Share By Region, 2024 Vs 2035 (%)
  • 8. Global Genomic Biomarker For Renal Disorders Market Share By Region, 2024 Vs 2035 (%)
  • 9. Global Genomic Biomarker For Other Diseases Indication Market Share By Region, 2024 Vs 2035 (%)
  • 10. Global Genomic Biomarker Market Share By End-User Industry, 2024 Vs 2035 (%)
  • 11. Global Genomic Biomarker For Diagnostic and Research Laboratories Market Share By Region, 2024 Vs 2035 (%)
  • 12. Global Genomic Biomarker For Hospitals Market Share By Region, 2024 Vs 2035 (%)
  • 13. Global Genomic Biomarker For Other End User Market Share By Region, 2024 Vs 2035 (%)
  • 14. Global Genomic Biomarker Market Share By Region, 2024 Vs 2035 (%)
  • 15. US Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 16. Canada Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 17. UK Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 18. France Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 19. Germany Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 20. Italy Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 21. Spain Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 22. Russia Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 23. Rest of Europe Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 24. India Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 25. China Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 26. Japan Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 27. South Korea Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 28. Australia and New Zealand Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 29. ASEAN Economies Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 30. Rest of Asia-Pacific Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 31. Latin America Genomic Biomarker Market Size, 2024-2035 ($ Million)
  • 32. Middle East and Africa Genomic Biomarker Market Size, 2024-2035 ($ Million)